Resistance to second-generation androgen receptor antagonists in prostate cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance to second-generation androgen receptor antagonists in prostate cancer
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume 18, Issue 4, Pages 209-226
Publisher
Springer Science and Business Media LLC
Online
2021-03-20
DOI
10.1038/s41585-021-00438-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer – a review of patent literature
- (2021) Hyunsoo Ha et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Targeting p300/CBP axis in lethal prostate cancer
- (2021) Jonathan Welti et al. Cancer Discovery
- Anti-tumor activity of NLG207 (formerly CRLX101) in combination with enzalutamide in preclinical prostate cancer models
- (2021) Keith T Schmidt et al. MOLECULAR CANCER THERAPEUTICS
- Reversal of Apalutamide and Darolutamide Aldo-Keto Reductase 1C3-Mediated Resistance by a Small Molecule Inhibitor
- (2020) Ahmed Morsy et al. ACS Chemical Biology
- A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration resistant prostate cancer.
- (2020) M.P. Kolinsky et al. ANNALS OF ONCOLOGY
- Towards Multidrug Adaptive Therapy
- (2020) Jeffrey West et al. CANCER RESEARCH
- Diverse AR Gene Rearrangements Mediate Resistance to Androgen Receptor Inhibitors in Metastatic Prostate Cancer
- (2020) Yingming Li et al. CLINICAL CANCER RESEARCH
- Combination radium-223 therapies in patients with bone metastases from castration-resistant prostate cancer: A review
- (2020) M.C. Cursano et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Androgen receptor variant-driven prostate cancer II: advances in clinical investigation
- (2020) Landon C. Brown et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation
- (2020) Zeda Zhang et al. CANCER CELL
- Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study
- (2020) Edwin M Posadas et al. CLINICAL CANCER RESEARCH
- Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment
- (2020) Ravi A. Madan et al. Clinical Genitourinary Cancer
- TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).
- (2020) Samuel R. Denmeade et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: Results of cohort 6 of the COSMIC-021 study.
- (2020) Neeraj Agarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor
- (2020) Remi Adelaiye-Ogala et al. MOLECULAR CANCER THERAPEUTICS
- Cross-resistance among next generation anti-androgen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer
- (2020) Jinge Zhao et al. MOLECULAR CANCER THERAPEUTICS
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer
- (2020) Alessio Crippa et al. Trials
- 68 Ga-prostate-specific membrane antigen tracers can alter the management of more than half of prostate cancer patients with biochemical recurrence
- (2020) Wei Diao et al. BJU INTERNATIONAL
- Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors
- (2020) Keith T. Schmidt et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia Patterns in Primary and Metastatic Prostate Cancer Environments
- (2019) Santosh Kumar Bharti et al. NEOPLASIA
- Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2019) Karim Fizazi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Matthew Smith et al. LANCET ONCOLOGY
- Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Lessons learned from the metastatic castration-resistant prostate cancer phase I trial of EPI-506, a first-generation androgen receptor N-terminal domain inhibitor.
- (2019) Ronan Le Moigne et al. JOURNAL OF CLINICAL ONCOLOGY
- Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
- (2019) Tatsuo Sugawara et al. INTERNATIONAL JOURNAL OF CANCER
- Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer
- (2019) William S. Chen et al. EUROPEAN UROLOGY
- FDA Approval Summary: Pembrolizumab for the treatment of microsatellite instability-high solid tumors
- (2019) Leigh Marcus et al. CLINICAL CANCER RESEARCH
- Treatment of Advanced Prostate Cancer
- (2019) Min Yuen Teo et al. Annual Review of Medicine
- Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer
- (2019) Robert B. Den et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- AR-V7 and AR-FL expression is associated with clinical outcome: a translational study in patients with castrate resistant prostate cancer
- (2019) Marzia Del Re et al. BJU INTERNATIONAL
- Multidrug cancer therapy in metastatic castrate-resistant prostate cancer: An evolution-based strategy
- (2019) Jeffrey B West et al. CLINICAL CANCER RESEARCH
- Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
- (2019) Michael J. Morris et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic correlates of clinical outcome in advanced prostate cancer
- (2019) Wassim Abida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer
- (2019) Pedro Isaacsson Velho et al. EUROPEAN UROLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination treatment in metastatic castration-resistant prostate cancer: can we safely boost efficacy by adding radium-223?
- (2019) Martina A. Knechel et al. CANCER BIOLOGY & THERAPY
- First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
- (2019) Sarina A. Piha-Paul et al. CLINICAL CANCER RESEARCH
- The Androgen Receptor Splice Variant AR-V7 as a Biomarker of Resistance to Androgen-axis Targeted Therapies in Advanced Prostate Cancer
- (2019) Tian Zhang et al. Clinical Genitourinary Cancer
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Degradation of proteins by PROTACs and other strategies
- (2019) Yang Wang et al. Acta Pharmaceutica Sinica B
- Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
- (2019) Meghan A. Rice et al. Frontiers in Oncology
- 846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
- (2019) W Abida et al. ANNALS OF ONCOLOGY
- Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
- (2019) E J Small et al. ANNALS OF ONCOLOGY
- Towards precision oncology in advanced prostate cancer
- (2019) Sheng-Yu Ku et al. Nature Reviews Urology
- The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
- (2019) Lisanne F. van Dessel et al. Nature Communications
- Genomics of lethal prostate cancer at diagnosis and castration resistance
- (2019) Joaquin Mateo et al. JOURNAL OF CLINICAL INVESTIGATION
- Measurement of NLG207 (formerly CRLX101) nanoparticle-bound and released camptothecin in human plasma
- (2019) Keith T. Schmidt et al. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
- Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial
- (2019) Daniel J Khalaf et al. LANCET ONCOLOGY
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth
- (2019) Sander AL Palit et al. eLife
- Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)
- (2018) Jonathan Welti et al. CLINICAL CANCER RESEARCH
- The potential of AR-V7 as a therapeutic target
- (2018) Takuma Uo et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review
- (2018) Orazio Caffo et al. Future Oncology
- A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer
- (2018) Laura Graham et al. INVESTIGATIONAL NEW DRUGS
- Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
- (2018) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study
- (2018) Benjamin A Teply et al. LANCET ONCOLOGY
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
- (2018) Maha Hussain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
- (2018) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metastatic Prostate Cancer
- (2018) Oliver Sartor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
- (2018) Matti Annala et al. Cancer Discovery
- Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer
- (2018) Howard I. Scher et al. JAMA Oncology
- Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
- (2018) Daniel Nava Rodrigues et al. JOURNAL OF CLINICAL INVESTIGATION
- Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
- (2018) E. David Crawford et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers
- (2018) Yan Zhang et al. Nature Communications
- Genomic analysis of DNA repair genes and androgen signaling in prostate cancer
- (2018) Kasey Jividen et al. BMC CANCER
- Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency
- (2018) Zafeiris Zafeiriou et al. EUROPEAN UROLOGY
- Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression
- (2018) Bing Song et al. JOURNAL OF CLINICAL INVESTIGATION
- Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
- (2018) Marcello Tucci et al. OncoTargets and Therapy
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations
- (2018) Fatima Karzai et al. Journal for ImmunoTherapy of Cancer
- Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss
- (2018) Johann S. de Bono et al. CLINICAL CANCER RESEARCH
- PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival
- (2017) K. Rahbar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study
- (2017) Tomasz M. Beer et al. EUROPEAN UROLOGY
- Significance of the TMPRSS2:ERG gene fusion in prostate cancer
- (2017) Zhu Wang et al. Molecular Medicine Reports
- WNT signalling in prostate cancer
- (2017) Virginia Murillo-Garzón et al. Nature Reviews Urology
- SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer
- (2017) Ping Mu et al. SCIENCE
- Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance
- (2017) Sheng Yu Ku et al. SCIENCE
- Mechanisms of Therapeutic Resistance in Prostate Cancer
- (2017) Mary Nakazawa et al. Current Oncology Reports
- Clinical relevance of androgen receptor alterations in prostate cancer
- (2017) Emma Jernberg et al. Endocrine Connections
- Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
- (2017) Daniel Crona et al. Cancers
- AR Signaling and the PI3K Pathway in Prostate Cancer
- (2017) Megan Crumbaker et al. Cancers
- N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer
- (2016) Etienne Dardenne et al. CANCER CELL
- Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer
- (2016) Santosh Gupta et al. CLINICAL CANCER RESEARCH
- Contemporary agents in the management of metastatic castration-resistant prostate cancer
- (2016) Anil Kapoor et al. CUAJ-Canadian Urological Association Journal
- Sequencing Treatment for Castration-Resistant Prostate Cancer
- (2016) Catherine E. Handy et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer
- (2016) Heather H. Cheng et al. EUROPEAN UROLOGY
- Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
- (2016) David Lorente et al. EUROPEAN UROLOGY
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
- (2016) David F. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Precision Oncology Medicine: The Clinical Relevance of Patient-Specific Biomarkers Used to Optimize Cancer Treatment
- (2016) Keith T. Schmidt et al. JOURNAL OF CLINICAL PHARMACOLOGY
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer
- (2016) I. A. Asangani et al. MOLECULAR CANCER RESEARCH
- The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
- (2016) Stefan Prekovic et al. MOLECULAR CANCER THERAPEUTICS
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
- (2016) Colin C. Pritchard et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
- (2016) Jennifer L. Bishop et al. Cancer Discovery
- Galeterone for the treatment of advanced prostate cancer: the evidence to date
- (2016) Emmanuel Antonarakis et al. Drug Design Development and Therapy
- Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
- (2016) Kathryn E. Ware et al. Oncotarget
- Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
- (2016) Alexander W. Wyatt et al. JAMA Oncology
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
- (2015) Y. Yamamoto et al. CLINICAL CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models
- (2015) Rute B. Marques et al. EUROPEAN UROLOGY
- PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate
- (2015) Roberta Ferraldeschi et al. EUROPEAN UROLOGY
- Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
- (2015) Orazio Caffo et al. EUROPEAN UROLOGY
- Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
- (2015) Daniel P Petrylak et al. LANCET ONCOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
- (2015) Anu-Maarit Moilanen et al. Scientific Reports
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
- (2013) J. D. Joseph et al. Cancer Discovery
- Overcoming mutation-based resistance to antiandrogens with rational drug design
- (2013) Minna D Balbas et al. eLife
- Hypoxia-Inducible Factors in Physiology and Medicine
- (2012) Gregg L. Semenza CELL
- Coordinated Action of Hypoxia-inducible Factor-1α and β-Catenin in Androgen Receptor Signaling
- (2012) Takakazu Mitani et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
- (2012) William Kevin Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
- (2011) M. J. Evans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2010) Yang-Min Ning et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia enhances transcriptional activity of androgen receptor through hypoxia-inducible factor-1α in a low androgen environment
- (2010) Takakazu Mitani et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- The relevance of a hypoxic tumour microenvironment in prostate cancer
- (2009) Grant D. Stewart et al. BJU INTERNATIONAL
- Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics
- (2009) G L Semenza ONCOGENE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started